Badrising, Sushil K. http://orcid.org/0000-0002-1994-3987
Louhanepessy, Rebecca D.
van der Noort, Vincent
Kieffer, Jacobien
Coenen, Jules L. L. M.
Hamberg, Paul
Beeker, Aart
Wagenaar, Nils
Lam, Marnix
Celik, Filiz http://orcid.org/0000-0002-6486-0435
Loosveld, Olaf J. L.
Oostdijk, Ad
Zuetenhorst, Hanneke
de Feijter, Jeantine M.
Dezentjé, Vincent O.
Ras-van Spijk, Suzan
Vegt, Erik
Haanen, John B.
van de Poll-Franse, Lonneke V.
Zwart, Wilbert
Bergman, Andries M. http://orcid.org/0000-0001-5223-2549
Funding for this research was provided by:
Bayer BV, Mijdrecht, The Netherlands
Article History
Received: 21 February 2021
Revised: 10 May 2021
Accepted: 16 June 2021
First Online: 26 August 2021
Declarations (Ethics)
:
: A.M.B. participated in Advisory Boards of Janssen Pharma, Bayer, Sanofi and Astellas, received speaking fees from Jansen Pharma, Bayer and Astellas, and received research grants from Sanofi and Astellas. J.M.F. participated in advisory boards of Janssen Pharma, Merck, and Pfizer. J.B.H. has provided consultation, attended advisory boards, and/or provided lectures for AIMM, Amgen, BioNTech, BMS, GSK, Ipsen, Merck Serono, Molecular Partners, MSD, Novartis, Pfizer, Roche/Genentech, Sanofi, Seattle Genetics, and Third Rock ventures. He is on the scientific advisory boards of IMM, BioNTech US, Gadeta, Immunocore, T-Knife and Neogene Therapeutics. He received grant support from Amgen, BioNTech US, BMS, MSD, and Novartis. He also has stock options in Neogene Therapeutics. All the remaining authors declare no competing interests.